Actively Recruiting
Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF
Led by Potsawat Surabotsopon · Updated on 2025-09-08
60
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.
CONDITIONS
Official Title
Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 80 years old
- Scheduled to undergo MIS TLIF surgery at 1 or 2 spinal levels
You will not qualify if you...
- Previous spine surgery
- HbA1C level greater than or equal to 7.5 mg%
- Allergy to any of the experimental medications
- History of systemic steroid use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Thammasat university hospital
Pathum Thani, Changwat Pathum Thani, Thailand, 12120
Actively Recruiting
Research Team
K
Konthorn Chankong, Master's degree
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here